NCT01897233View on ClinicalTrials.gov

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Cystic Fibrosis

Interventions

DRUG

Lumacaftor

DRUG

Ivacaftor

Trial Locations (20)

Unknown

Birmingham

Tucson

Long Beach

Palo Alto

Aurora

Atlanta

Indianapolis

Boston

Kansas City

St Louis

Buffalo

Rochester

Syracuse

Charleston

Austin

Salt Lake City

Norfolk

Seattle

Milwaukee

Toronto

All Listed Sponsors

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY

NCT01897233 - Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation | Biotech Hunter | Biotech Hunter